Clinical trials: sponsored by Canadian Cancer Trials Group
Prostate Carcinoma
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
The purpose of this study is to evaluate the dose of High Dose Rate (HDR) brachytherapy chosen for this study as well as a commonly used alternate form of brachytherapy called low dose rate (or seed) brachytherapy.
- Trial name
- NCT02960087
- Testing
- Low dose rate brachytherapy, High dose rate brachytherapy
- Where
- 7 sites in Canada
- Volunteers
- 334 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a…
- Trial name
- OPTION-DDR (NCT06439225)
- Testing
- Docetaxel, Carboplatin
- Where
- 14 sites in Canada
- Volunteers
- 236 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body…
- Trial name
- ASCENDE-SBRT (NCT06235697)
- Testing
- Radiation, Radiation SBRT only, ADT
- Where
- 57 sites in United States, Canada
- Volunteers
- 710 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
This research is being done because investigators involved in this study would like to compare image guided external beam radiation therapy (IGRT) to IGRT plus HDR brachytherapy boost to see which treatment is better and what the…
- Trial name
- NCT01982786
- Testing
- Image guided external beam radiotherapy with or without brachytherapy boost, Brachytherapy
- Where
- 9 sites in Canada
- Volunteers
- 57 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
The purpose of this study is to determine if the combination of endocrine therapy and Palbociclib at a daily dose of 100 mg will result in a better response to therapy with fewer dose interruptions than the proposed dosing…
- Trial name
- NCT02630693
- Testing
- Palbociclib 100mg, Palbociclib 125mg, Fulvestrant or Tamoxifen or Aromatase Inhibitor
- Where
- 22 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).
- Trial name
- FINER (NCT04650581)
- Testing
- Ipatasertib, Fulvestrant
- Where
- 39 sites in Australia, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Canadian Cancer Trials Group
Rectal Cancer
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer.
- Trial name
- NCT03259035
- Testing
- Folfox Protocol, Capox
- Where
- 11 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Canadian Cancer Trials Group
Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
This research is being done because it is not yet known what dose of romidepsin in combination with gemcitabine, dexamethasone, and cisplatin (GDP) can be given safely to patients with peripheral T-cell lymphoma, nor what type…
- Trial name
- NCT01846390
- Testing
- Gemcitabine, Dexamethasone, Cisplatin
- Where
- 6 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Canadian Cancer Trials Group
Solid Malignancies
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
The purpose of this study is to find the highest dose of durvalumab or of durvalumab with tremelimumab that can be tolerated without causing very severe side effects when receiving standard chemotherapy and to see what effects…
- Trial name
- NCT02537418
- Testing
- durvalumab, tremelimumab
- Where
- 7 sites in Canada
- Volunteers
- 153 people
- Sponsor
- Canadian Cancer Trials Group
Lymphoma, Non-Hodgkin, Multiple Myeloma
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- CAPTUR (NCT03297606)
- Testing
- Olaparib, Dasatinib, Nivolumab plus Ipilimumab
- Where
- 10 sites in Canada
- Volunteers
- 720 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of disease and relieve some symptoms of cancer.
- Trial name
- NCT03568422
- Testing
- CFI-402257, Paclitaxel
- Where
- 4 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer Metastatic
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
The purpose of this study is to compare the effects of ablative therapy (radiation or surgery) to all sites of disease combined with standard treatments on prostate cancer, compared to the standard or usual treatments used to…
- Trial name
- PLATON (NCT03784755)
- Testing
- Ablative Radiation Therapy, Standard of care
- Where
- 18 sites in Canada
- Volunteers
- 409 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body.
- Trial name
- NCT04663997
- Testing
- 177Lu-PSMA-617, Docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Canadian Cancer Trials Group
Oropharyngeal Squamous Cell Carcinoma
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back.
- Trial name
- NCT03410615
- Testing
- Radiation, Cisplatin, Durvalumab
- Where
- 26 sites in Belgium, Canada and 2 more
- Volunteers
- 129 people
- Sponsor
- Canadian Cancer Trials Group
Advanced/Metastatic Solid Tumours
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
This research is being done because these viruses have been shown to shrink tumours in animals and human tumour samples by selectively killing cancer cells and creating an immune response to the tumour antigen contained in the…
- Trial name
- NCT02285816
- Testing
- MG1MA3, AdMA3
- Where
- 4 sites in Canada
- Volunteers
- 56 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib.
- Trial name
- NCT02905318
- Testing
- Palbociclib
- Where
- 7 sites in Canada
- Volunteers
- 19 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.
- Trial name
- NCT04176848
- Testing
- CFI-400945, Durvalumab
- Where
- 5 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Oropharyngeal Cancer
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.
- Trial name
- EVADER (NCT03822897)
- Testing
- Radiation, Cisplatin
- Where
- 14 sites in Canada
- Volunteers
- 103 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Cancer
RP-6306 in Patients With Advanced Cancer
This study is being done to answer the following questions: Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment? If there are specific biomarkers, do patients have an…
- Trial name
- NCT05605509
- Testing
- RP-6306, Gemcitabine, FOLFIRI Protocol
- Where
- 6 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Canadian Cancer Trials Group
Hodgkin Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
- Trial name
- NCT05180097
- Testing
- Gemcitabine, Dexamethasone, Cisplatin
- Where
- 18 sites in Australia, Canada
- Volunteers
- 84 people
- Sponsor
- Canadian Cancer Trials Group